Myopia Management: The Science of Low-Dose Atropine

Clinical Insights from Whole Health Compounding Pharmacy Glebe

Myopia (nearsightedness) has transitioned from a simple vision correction issue to a significant global health priority. Current projections indicate that by 2050, nearly 50% of the world’s population will be myopic. In Ottawa, as in many urban centers, the shift toward increased “near-work” and reduced outdoor time has accelerated this trend among children.

While glasses and contact lenses correct the blur, they do not treat the underlying cause: the excessive elongation of the eyeball (axial length). Low-dose Atropine has emerged as a gold-standard pharmaceutical intervention to slow this progression.

The Evolution of the Evidence: ATOM to LAMP

The Evolution of the Evidence Myopia Management

Historically, 1.0% Atropine was used to dilate the pupil, but its side effects (light sensitivity and blurred near vision) made it impractical for daily myopia control. Scientific breakthroughs have shifted the focus to ultra-low concentrations:

The ATOM2 Study: Established that low doses, particularly 0.01%, could significantly slow myopia progression with a drastically improved safety profile.
The LAMP Study (2019–2025): Recent multi-year data from the Low-Concentration Atropine for Myopia Progression (LAMP) study suggests a dose-dependent response. Researchers found that 0.05% may offer the optimal balance of efficacy—often slowing progression by up to 50%—while maintaining high tolerability in children.
CHAMP Trial (2023-2024): Large-scale international Phase III trials have confirmed that preservative-free low-dose formulations are effective across diverse ethnicities, leading to recent advancements in regulatory approvals worldwide.

Why Compounding is Essential

Low-dose Atropine (0.01% to 0.05%) is not available as a mass-produced, commercial product in Canada. It must be precisely formulated by a specialized pharmacy.

At Whole Health Compounding Pharmacy Glebe, we facilitate this specialized care by:

Sourcing Pharmaceutical Grade Ingredients: We source high-purity Atropine from PCCA-certified labs to ensure clinical-grade efficacy.
Custom Concentration: Every child’s eyes are different. Following a referral from an Ottawa-based optometrist or ophthalmologist, we obtain the exact concentration (0.01%, 0.025%, or 0.05%) required for the specific patient.

Key Research Findings for 2026

“Atropine does not just clear vision; it changes the trajectory of ocular health.” > Latest meta-analyses (published in Frontiers in Medicine, 2026) confirm that early intervention with low-dose atropine reduces the risk of high-myopia complications later in life, such as retinal detachment and myopic maculopathy, by limiting axial elongation in the early school years.

Our Role in the Ottawa Community

Located in the heart of the Glebe, we serve patients across the Ottawa region, ensuring that children have access to the most stable and effective formulations of myopia-control drops. We work in tandem with local eye care specialists to provide a seamless transition from diagnosis to daily treatment.

Are you an Ottawa parent or healthcare provider interested in a consultation?

Contact Whole Health Compounding Pharmacy Glebe at 613-231-7770 to learn more about our compounding standards and delivery options throughout the city.

Frequently Asked Questions

Is low-dose atropine a “cure” for myopia?

No. Myopia is currently considered irreversible because it involves the physical elongation of the eyeball. Low-dose atropine is a management strategy designed to slow down the rate of that elongation. The goal is to prevent a child from reaching “high myopia” (typically defined as a prescription greater than -5.00 or -6.00 diopters), which significantly reduces the lifetime risk of retinal issues.

Why can’t I just buy these drops at a regular pharmacy?

Standard commercial atropine is typically manufactured at a 1.0% concentration, which is too strong for daily myopia management and causes significant side effects like light sensitivity. The low doses used in recent clinical trials—such as 0.01%, 0.025%, and 0.05%—are not currently mass-produced as “off-the-shelf” products in Canada. They must be custom-prepared by a compounding pharmacy in a sterile lab environment.

How long does a child typically need to use the drops?

Current research, including the long-term LAMP study, suggests that treatment is most effective during the years of most rapid eye growth, usually between the ages of 5 and 16. Your optometrist or ophthalmologist will monitor your child’s axial length and prescription every 6 months to determine when it is safe to taper off the medication.

Are there side effects to the ultra-low doses?

At the 0.01% concentration, side effects are extremely rare. At slightly higher “low doses” like 0.05%, some children may experience a slight increase in pupil size or mild “near-blur” when reading. Because we compound these locally at Whole Health, we can adjust the formulation (for example, making it preservative-free) to improve comfort if a child has sensitive eyes.

Can these drops be used with glasses or contact lenses?

Yes. In fact, low-dose atropine is often used as a combination therapy. While the drops work on the biological growth of the eye, the child still needs glasses or specialized contact lenses (like MiSight or Ortho-K) to see clearly during the day. Recent 2024-2025 data suggest that combining atropine with specialized myopia-control glasses may offer an even greater slowing effect than either treatment alone.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice. Low-dose atropine is a prescription medication that must be used under the supervision of a licensed eye care professional. Contact Whole Health Compounding Pharmacy Glebe to discuss how we work with your prescriber to provide customized ophthalmic solutions.